logologo
QuantliQuantli

Coya Therapeutics Inc

COYA

NASDAQ

Biotechnology

$4.79

USD

+0.12 (+2.57%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $109.55M

Volume 113.6K

Price (USD)
Price (USD)

About Coya Therapeutics Inc

The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-12-29.

CEO

Dr. Arun Swaminathan

HQ

Houston, TEXAS, US

Founded

2022

Employees

8

Quantli Score

8.4

Outperform

Fin. Health

8.1

Profitability

7.6

Growth

9.0

Cash-Flow Q.

8.8

Key Metrics

6 metrics our research team weighs before forming a view on COYA.

Based on Quantli research · SEC filings · as of Q2 2026

METRIC

VALUE

CHANGE

TREND (3Y)

Revenue Growth (TTM)

1793.8%

+1889.3 pp

Gross Margin (TTM)

100.0%

0.0 pp

Operating Margin (TTM)

-288.7%

+5053.6 pp

Net Margin (TTM)

-270.2%

+4532.9 pp

ROE (TTM)

-50.1%

+21.8 pp

Free Cash Flow (TTM)

$-15.72M

Financial Snapshot

Full Financials

Revenue

$8.02M

+1793.8%

YoY

Gross Margin

100%

TTM

0.0%

YoY

Net Income

$-21.67M

-6.5%

YoY

Operating Cash Flow

$-15.72M

+4.6%

YoY

Key Statistics

Open

$4.70

Previous Close

$4.67

Day Range

$4.55 - $4.85

52 Week Range

$3.71 - $7.75

Volume

113.6K

Average Volume (10 Days)

150.0K

Dividend Yield

Valuation Measurement

Market Cap

$109.55M

P/E Ratio (TTM)

P/S Ratio (TTM)

13.66

Price / Book

2.53

Financial Highlights

Profit Margin

-270.2%

Return on Assets

-45.8%

Return on Equity

-50.1%

Revenue (TTM)

$8.02M

Net Income (TTM)

$-21.67M

Diluted EPS (TTM)

-$1.07

Total Cash (MRQ)

$43.18M

Levered FCF (TTM)

$-15.72M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Go deeper on COYA

Similar Stocks

XGN

Exagen Inc

$6.66

+1.2%

INDP

Indaptus Therapeutics Inc

$1.07

+0.9%

VTVT

vTv Therapeutics Inc

$30.12

-2.4%

GNLX

Genelux Corp

$2.74

+4.2%

CADL

Candel Therapeutics Inc

$11.72

-0.7%

ANIX

Anixa Biosciences Inc

$3.18

-0.6%

INO

Inovio Pharmaceuticals Inc

$1.09

+21.1%

BDTX

Black Diamond Therapeutics Inc

$2.02

0.0%

Earnings Calendar

Next Earnings

Estimated Q2 Release

Aug 18

Est. EPS

Adjusted consensus estimate

-$0.35

Analyst Consensus

Buy

Based on 2 analyst ratings

Avg Target: $13.00

(+171.4% upside)

High: $14.00 · Low: $12.00

Strong Buy

0%

Buy

100%

Hold

0%

Sell

0%

Strong Sell

0%

View full analyst ratings